In the days of the Armada, a fleet of warships, the scuttlebutt was the rumor or gossip that would spread throughout the ship. Today, Armada Law Corp presents The Scuttlebutt, a daily summery of news articles that people within the cannabis, hemp and plant medicine industries are chatting about along with links to the full articles.
In today’s news:
#californiacannabis – “AB-374 is now in the hands of Gov. Gavin Newsom after passing through with broad bipartisan support.
The bill would allow local jurisdictions to license Amsterdam-style cannabis cafes at dispensaries….
Cannabis smoke lounges are already legal in some cities. But selling food and drinks inside is not.
“This would entice people to stay and also help us promote our business with revenue as well,” Andrew said.”
#Psychedelics – “A new 11-site study — the fifth randomized trial of psilocybin for depression reported during the past 3 years — was published recently (JAMA 2023; 330:843. opens in new tab). About 100 depressed patients (mean age, 41) who were not receiving medication were randomized to a single oral dose of psilocybin (25 mg) or active placebo (niacin). Average duration of the current depressive episode was about 1 year, 12% of patients were treatment-resistant, and most patients had had at least one prior depressive episode. Treatment was given in a 7- to 10-hour session with music provided through headphones in a comfortable room, after 6 to 8 hours of preparatory sessions with doctoral-level facilitators; this phase was followed by 4 hours of post-dose “integration sessions,” in which patients discussed their treatment experiences with the research team.
Psilocybin recipients, compared with placebo recipients, were more likely to have sustained responses (42% vs. 11%, through day 43) and remission (25% vs 9%), and they had greater improvement in measures of quality of life. Headache, nausea, and “visual perceptual effects” were common initial adverse effects, but they resolved within 10 days. In a trial published in 2022 (N Engl J Med 2022; 387:1637. opens in new tab) response and remission rates were similar to those of the 2023 study. Several participants in the 2022 study reported suicidal ideation or self-injury, but those adverse effects weren’t noted in the 2023 study.
Read More: https://www.jwatch.org/na56577/2023/09/13/antidepressant-effects-psychedelic-drug-psilocybin
#cannabisresearch – “A new study indicates a link between the co-use of tobacco and cannabis and heightened rates of anxiety and depression. Analyzing data from the COVID-19 Citizens Health Study, researchers delved into the substance use habits of 53,843 US adults between 2020 and 2022. Co-users of both substances exhibited roughly 1.8 times the likelihood of having these mental health challenges than non-users. While causation isn’t established, the intertwined use of these substances points to potential mental health risks.
Read More: https://neurosciencenews.com/anxiety-tobacco-cannabis-depression-23916/